J&J Invests $1B+ in Pennsylvania Cell Therapy Facility – Expands Manufacturing for Cancer and Neurology Pipeline
Johnson & Johnson (J&J, NYSE: JNJ) announced a more than USD 1 billion investment to build a next‑generation...
Johnson & Johnson
J&J’s RYBREVANT SC Dosing Approved by EC – Expands Subcutaneous Options Across All NSCLC Indications
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved an extension...
Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar
Bio-Thera Solutions Inc. (SHA: 688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its...
J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients
Johnson & Johnson (J&J, NYSE: JNJ) announced that Darzalex Faspro (daratumumab and hyaluronidase-fihj) has received National...
J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human Use...
J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...
HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance
Hangzhou HealZen Therapeutics Co., Ltd. announced a global partnership with an undisclosed American biotechnology company...
J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
Johnson & Johnson (J&J, NYSE: JNJ) reported fourth‑quarter revenue of $24.6 billion, up 9.1% year‑on‑year (YOY), bringing...
Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
Bio‑Thera Solutions Inc. (SHA: 688177) announced a licensing agreement granting Gedeon Richter Plc. commercialization rights...
J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced positive topline results from the Phase 3 MajesTEC‑9 study of...
Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
Johnson & Johnson (J&J, NYSE: JNJ) announced a voluntary agreement with the Trump Administration to...
J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase 2b DUPLEX‑AD proof‑of‑concept study evaluating JNJ‑95475939...
J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Amivantamab Injection (Subcutaneous), marketed as RYBREVANT, received...
J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has extended the...
Johnson & Johnson’s TECVAYLI Gets FDA Priority Review for Myeloma Combo
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA selected the teclistamab MajesTEC‑3 supplemental...
Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...
Kelonia JNJ Partnership Targets In Vivo CAR-T for Multiple Myeloma
Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop...
Johnson & Johnson China PINS Head Alex He to Depart, Driving Leadership Transition Amid Key NRDL Product Success
Johnson & Johnson (J&J, NYSE: JNJ) China confirmed a significant leadership change today, announcing that...
BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients
Bristol‑Myers Squibb (BMS, NYSE: BMY) and Johnson & Johnson (J&J, NYSE: JNJ) announced the premature...
Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915
Johnson & Johnson (J&J, NYSE: JNJ) announced a definitive agreement to acquire Halda Therapeutics in an all‑cash...